| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.035 | 0.4 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | 0.034 | 0.4 |
| mRNA | NSC632839 | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | 0.036 | 0.4 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.034 | 0.4 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | 0.035 | 0.4 |
| mRNA | AZD6244 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | avrainvillamide | CTRPv2 | pan-cancer | AAC | 0.038 | 0.4 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |